Gj. Harris et al., Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease, BRAIN, 122, 1999, pp. 1667-1678
The aim of this study was to examine basal ganglia volumes and regional cer
ebral blood flow in asymptomatic subjects at-risk for Huntington's disease
who had undergone genetic testing, We determined which measures were the be
st 'markers' for the presence of the mutation and for the onset of symptoms
, Twenty subjects who were Huntington's disease gene mutation-positive and
24 Huntington's disease gene mutation-negative participants, all of whom ha
d a parent with genetically confirmed Huntington's disease, and were theref
ore 50% at-risk for inheriting the Huntington's disease gene mutation, were
included in the study, To evaluate basal ganglia structure and function, M
RI and single photon emission computed tomography (SPECT) were used. Quanti
tative measures of regional volumes and relative measures of regional perfu
sion were calculated. SPECT and MRI scans were co-registered so that MRI an
atomy could be used accurately to place SPECT regions, Estimated years-to-o
nset in the mutation-positive subjects was calculated based on a regression
formula that included gene (CAG)(n) repeat length and parental age of onse
t, Changes in imaging measures in relation to estimated years-to-onset were
assessed. The imaging measure that was most affected in mutation-positive
subjects was putamen volume, This was also the measure that correlated most
strongly with approaching onset. In subjects greater than or equal to 7 ye
ars from estimated onset age, the putamen volume measures n ere similar to
those of the mutation-negative subjects, However, in subjects 56 years from
estimated onset age, there were dramatic reductions in putamen volume, res
ulting in >90% discrimination from both the far-from-onset and the mutation
-negative subjects. Caudate volume and bicaudate ratio also showed a signif
icant decline in the close-to-onset subjects, although to a lesser degree t
han putamen volume reductions. Furthermore, SPECT basal ganglia perfusion d
eficits were observed in mutation-positive subjects. Imaging markers of neu
ropathological decline preceding clinical onset are important for assessing
the effects of treatments aimed at slowing the course of Huntington's dise
ase. The current study suggests that quantitative assessment of basal gangl
ia may provide a means to track early signs of decline in individuals with
the Huntington's disease gene mutation prior to clinical onset.